[go: up one dir, main page]

MX2009010336A - Composicion de vehiculo de rapido suministro de acido nucleico. - Google Patents

Composicion de vehiculo de rapido suministro de acido nucleico.

Info

Publication number
MX2009010336A
MX2009010336A MX2009010336A MX2009010336A MX2009010336A MX 2009010336 A MX2009010336 A MX 2009010336A MX 2009010336 A MX2009010336 A MX 2009010336A MX 2009010336 A MX2009010336 A MX 2009010336A MX 2009010336 A MX2009010336 A MX 2009010336A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid delivery
delivery carrier
prompt
carrier composition
Prior art date
Application number
MX2009010336A
Other languages
English (en)
Inventor
Hidekazu Toyobuku
Takeuchi Hirofumi
Yasuyuki Hira
Koji Nakano
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2009010336A publication Critical patent/MX2009010336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un objetivo de la presente invención es proveer una composición de vehículo para el suministro de ácido nucleico, el cual puede suministrar eficientemente un ácido nucleico a la células cuando un ácido nucleico tal como ARNip se administra a células derivadas de animales o animales y también tiene baja toxicidad y alta seguridad y una composición para el suministro de ácido nucleico que contiene la composición de vehículo y ácido nucleico; un vehiculo para suministro de ácido nucleico se prepara al utilizar (A) una diacilfosfatidilcolina, (B) al menos un elemento seleccionado del grupo que consiste en colesterol y derivados del mismo y (C) una amina primaria alifática; también, una composición para suministro de ácido nucleico se prepara al mezclar el vehículo para el suministro de ácido nucleico con un ácido nucleico.
MX2009010336A 2007-03-26 2008-03-26 Composicion de vehiculo de rapido suministro de acido nucleico. MX2009010336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007079944 2007-03-26
PCT/JP2008/055730 WO2008117828A1 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物

Publications (1)

Publication Number Publication Date
MX2009010336A true MX2009010336A (es) 2009-10-16

Family

ID=39788561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010336A MX2009010336A (es) 2007-03-26 2008-03-26 Composicion de vehiculo de rapido suministro de acido nucleico.

Country Status (26)

Country Link
US (1) US9315828B2 (es)
EP (1) EP2140870B1 (es)
JP (1) JP5349293B2 (es)
KR (1) KR101459391B1 (es)
CN (1) CN101646443B (es)
AR (1) AR065847A1 (es)
AU (1) AU2008230379B2 (es)
BR (1) BRPI0809634A2 (es)
CA (1) CA2682490A1 (es)
CO (1) CO6241127A2 (es)
DK (1) DK2140870T3 (es)
ES (1) ES2542864T3 (es)
HR (1) HRP20150927T1 (es)
HU (1) HUE027053T2 (es)
IL (1) IL201116A0 (es)
MX (1) MX2009010336A (es)
MY (1) MY151450A (es)
NZ (1) NZ579804A (es)
PL (1) PL2140870T3 (es)
PT (1) PT2140870E (es)
RU (1) RU2476229C2 (es)
SI (1) SI2140870T1 (es)
TW (1) TWI428135B (es)
UA (1) UA97143C2 (es)
WO (1) WO2008117828A1 (es)
ZA (1) ZA200906576B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2753703A1 (en) * 2009-03-04 2010-09-10 Hirofumi Takeuchi Nucleic acid complex and nucleic acid-delivering composition
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
AU2011305617A1 (en) 2010-09-20 2013-02-21 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
JP6029131B2 (ja) * 2011-12-28 2016-11-24 国立研究開発法人国立循環器病研究センター 核酸導入剤、核酸導入方法及び細胞
EP3449001B1 (en) 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
US10975388B2 (en) 2016-12-14 2021-04-13 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184834A1 (en) 1994-03-11 1995-09-14 Yoshiyuki Mori Liposome preparation
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6835395B1 (en) * 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
JPH10313872A (ja) 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
AU751439B2 (en) * 1997-09-16 2002-08-15 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
AU772847B2 (en) * 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
WO2004064731A2 (en) * 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
WO2005000796A1 (ja) * 2003-06-27 2005-01-06 Sumitomo Chemical Company, Limited アミド化合物およびそれを用いた植物病害の防除方法
CN101291653B (zh) * 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
EP1663315B1 (en) * 2003-09-17 2011-01-05 Rodos BioTarget GmbH Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
EP1759691A1 (en) 2003-11-20 2007-03-07 Delex Therapeutics Inc. Stable liposome compositions
AT500143A1 (de) 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
EP1773857A4 (en) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
CA2587411A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
EP1912679A4 (en) * 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Also Published As

Publication number Publication date
NZ579804A (en) 2012-05-25
ZA200906576B (en) 2010-11-24
KR101459391B1 (ko) 2014-11-07
JPWO2008117828A1 (ja) 2010-07-15
CA2682490A1 (en) 2008-10-02
HK1139041A1 (en) 2010-09-10
US20100063131A1 (en) 2010-03-11
AU2008230379A1 (en) 2008-10-02
HRP20150927T1 (hr) 2015-10-09
EP2140870A1 (en) 2010-01-06
PL2140870T3 (pl) 2015-11-30
CN101646443A (zh) 2010-02-10
CN101646443B (zh) 2015-01-14
JP5349293B2 (ja) 2013-11-20
IL201116A0 (en) 2010-05-17
EP2140870B1 (en) 2015-06-24
TW200902035A (en) 2009-01-16
MY151450A (en) 2014-05-30
UA97143C2 (ru) 2012-01-10
CO6241127A2 (es) 2011-01-20
KR20090130056A (ko) 2009-12-17
AR065847A1 (es) 2009-07-08
TWI428135B (zh) 2014-03-01
SI2140870T1 (sl) 2015-10-30
HUE027053T2 (en) 2016-08-29
ES2542864T3 (es) 2015-08-12
AU2008230379B2 (en) 2012-12-06
PT2140870E (pt) 2015-09-15
RU2009139246A (ru) 2011-05-10
RU2476229C2 (ru) 2013-02-27
US9315828B2 (en) 2016-04-19
WO2008117828A1 (ja) 2008-10-02
BRPI0809634A2 (pt) 2014-09-23
EP2140870A4 (en) 2011-09-07
DK2140870T3 (en) 2015-07-20

Similar Documents

Publication Publication Date Title
MX2009010336A (es) Composicion de vehiculo de rapido suministro de acido nucleico.
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
UA108988C2 (en) PESTICIDAL COMPOSITION, INCLUDING POLYMERIC AUXILIARY SUBSTANCES
MX2010005451A (es) Sistema para la liberacion en una celula positiva para xcr1 y usos de este.
WO2008011636A3 (en) Targeted gene delivery for dendritic cell vaccination
NZ584048A (en) Lipopeptides for delivery of nucleic acids
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2008129548A3 (en) A system for delivering therapeutic agents into living cells and cells nuclei
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2007118245A3 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2011071535A3 (en) Compositions and methods for inhibiting human host cell factors required for influenza virus replication
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
MY149917A (en) Nuceic acid complex and nucleic acid delivery composition
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
WO2009129208A3 (en) Compositions and methods of inducing endoplasmic reticulum stress reponse
EP2692723A8 (en) Aryloxy dihalopropenyl ether compound and use thereof
WO2009149397A3 (en) Respiratory syncytial virus renders dendritic cells tolerogenic
WO2008052046A3 (en) Compositions for coating cell membranes and methods of use thereof
WO2008087774A1 (ja) 抗酸化剤
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
AR057553A1 (es) Composicion portadora para el suministro de un acido nucleico
EP2851426A3 (en) Compositions and methods for inhibiting expression of RRM2 genes

Legal Events

Date Code Title Description
FG Grant or registration